Business Context and Reporting Period
Company: Boston Scientific Corporation
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 1997
Industry: Minimally invasive medical devices (cardiology, electrophysiology, gastroenterology, neuro-endovascular, radiology, urology, vascular surgery).
Boston Scientific is a global developer and marketer of medical devices designed to reduce procedural trauma and recovery time. The company's growth strategy relies heavily on product innovation, focused marketing through seven principal divisions, and strategic acquisitions. In 1997, the company completed the integration of most 1995-1996 acquisitions and was in the process of integrating Target Therapeutics, Inc.
Key Financial Metrics
Revenue: Net sales for 1997 were $1.87 billion, a substantial increase from $1.8 million in 1979.
Revenue Mix: Approximately 79% of net sales were derived from vascular products and 21% from nonvascular products.
Geographic Sales: International sales accounted for approximately 43% of net sales in 1997 (up from 40% in 1996 and 35% in 1995).
Research & Development: Expenditures totaled $167 million, representing approximately 9% of 1997 net sales.
Allowances for Uncollectible Amounts: The balance at the end of 1997 was $30.479 million, with additions charged to costs and expenses of $10.718 million.
Note: Specific figures for net profit, operating income, cash flow, debt levels, and liquidity ratios are not provided in the text of this filing, as the detailed financial statements are incorporated by reference from the 1997 Annual Report to Shareholders.
Material Changes and Operational Highlights
- Acquisitions and Alliances: Between 1995 and 1997, the company acquired or merged with significant entities including SCIMED Life Systems, Cardiovascular Imaging Systems, Vesica Medical, Meadox Medicals, Heart Technology, EP Technologies, Symbiosis Corp, Endotech/MinTec, and Target Therapeutics. Strategic alliances were formed with Medinol Ltd., Nitinol Medical Technologies, Urologix, Aida Engineering, and Angiotech Pharmaceuticals.
- International Expansion: The company operates manufacturing facilities in Ireland and has direct sales operations in over 25 countries. International sales growth outpaced domestic growth, increasing its share of total revenue.
- Facility Expansion: In 1997, the company completed 143,000 square feet of workspace in Galway, Ireland, and acquired a new manufacturing facility in Cork, Ireland. Domestic expansion included a new 248,000 square foot building in Maple Grove, Minnesota, and consolidation of operations in Oakland, New Jersey.
- Workforce: As of December 31, 1997, the company employed over 11,000 people, including approximately 3,100 in international operations.
Outlook, Risks, and Management Commentary
Guidance and Outlook: Management expects to complete the integration of Target Therapeutics by the end of 1998. The company anticipates continued growth driven by the expansion of international operations in Asia, Eastern Europe, and Latin America. A key strategic focus is the launch of the NIR coronary stent in the U.S. and Japan, pending FDA approval expected mid-year 1998.
Risks and Contingencies:
- Integration Risk: The complexity of integrating numerous major acquisitions presents a significant degree of difficulty; failure to integrate effectively could adversely affect operating results.
- Regulatory Risk: The company relies on FDA and international regulatory approvals. Delays or denials, particularly for the NIR stent, could impact revenue and market share.
- Reimbursement and Pricing Pressure: Managed care, cost containment, and consolidation among healthcare providers are exerting downward pressure on selling prices and gross margins, particularly in Europe (Germany, France) and Japan.
- Foreign Currency: With 43% of sales in foreign currencies, the company is exposed to exchange rate fluctuations which may impact margins.
- Intellectual Property: The company is involved in patent litigation, including a suit filed in March 1998 against Circon Corporation and a countersuit by Circon. Adverse outcomes could result in significant liabilities or restrictions on product sales.
Investor Verification Checklist
- Verify the specific net income, operating cash flow, and debt-to-equity ratios in the full 1997 Annual Report to Shareholders (Exhibit 13.1), as these figures are not explicitly stated in the 10-K text.
- Monitor the status of the FDA Pre-Market Approval (PMA) for the NIR coronary stent, filed January 28, 1998, as its approval is critical for future growth.
- Review the progress of the Target Therapeutics integration to ensure it is on track for completion by the end of 1998.
- Assess the impact of foreign currency hedging strategies on margins given the 43% international sales exposure.
- Track the outcome of the patent litigation with Circon Corporation regarding ureteral stents and vapor electrodes.